YLYi Liu

Yi Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yi Liu has a total of 84 co-authors. Here are the top co-authors by number of shared publications:

  • Yuguo Du

    Chinese Academy of Sciences

    7 shared publications
  • Huili Liu

    Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education Yantai University Yantai China

    5 shared publications
  • Jun Liu

    State Key Laboratory of Environmental Chemistry and Eco-Toxicology, Research Center for Eco-Environmental Sciences

    5 shared publications
  • Yuguo Du

    Chinese Acad Sci, Res Ctr Ecoenvironm Sci, State Key Lab Environm Chem & Ecotoxicol, Beijing 100085, Peoples R China

    5 shared publications
  • Hongbo Wang

    Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education Yantai University Yantai China

    3 shared publications
  • Hongbo Wang

    Space Information Research Institute and Zhejiang Key Laboratory of Space Information Sensing and Transmission, Hangzhou Dianzi University, Hangzhou, China

    3 shared publications

Latest Publications

  • Discovery of Bistratamides as Efficacious Reversers of P‐Glycoprotein‐Mediated Multidrug Resistance

    by Ke Wang, Sihan Qiang, Ziqiang Sun, Shanshan Wang, Yunchang Yin, Zongliang Liu, Xin Yu, Huili Liu, Yi Liu, Hongbo Wang

    Although strategies combining multidrug resistance (MDR) reversal agents with chemotherapeutic drugs have demonstrated efficacy in clinical practice, their widespread application remains limited by potential toxicity. Natural thiazole‐containing macrocycles have displayed promising MDR reversal potential. However, the 18‐membered macrocycles bistratamides, despite their structural similarity to the known MDR reversal agent dendroamide A, remain unexplored regarding potential roles as MDR reversal agents and their molecular targets. In this study, we report the synthesis and initial discovery of bistratamides as potential MDR reversal agents. Structure–activity relationship analysis revealed that the oxazoline or oxazole motifs embedded within the macrocyclic framework are essential for MDR reversal activity in bistratamides. The oxazoline‐containing bistratamide derivative 15 demonstrated the greatest synergistic anticancer effect among the examined compounds, exhibiting > three‐fold greater activity than verapamil (VRP) with no observable toxicity in KBV cells and normal human podocytes. The MDR reversal effect of 15 in combination with paclitaxel was further validated through combination assays and flow cytometry. Subsequent rhodamine 123 (Rh123) accumulation assays and western blotting confirmed that 15  exerts its MDR reversal activity by inhibiting P‐gp efflux function rather than affecting its expression. Our findings suggest that 15 represents a promising starting point for the development of novel chemosensitizing agents.

  • Discovery of valine thiazole-containing derivatives as potent reversers of P-glycoprotein–mediated multidrug resistance

    by Sihan Qiang, Ke Wang, Shanshan Wang, Zongliang Liu, Xin Yu, Zuguang Yin, Yuxin Feng, Huaiyu Wang, Huili Liu, Hongbo Wang, et al.

  • Efforts toward the Total Synthesis of Thuggacin A

    by Yang Liu, Yi Liu, Jun Liu, Minhao Chen, Yuxin Cui, Xintong Zhou, Kaixia Mi, Yuguo Du

    Thuggacin A (1) is a 17-membered-ring-polyketide antibiotic compound with excellent antituberculosis activity. The total synthesis of thuggacin A has not yet been reported so far. Herein, we disclose our efforts toward the convergent total synthesis of thuggacin A. The key synthetic features include our own one-pot cascade thiazole formation, Evans syn-aldol, Mukaiyama asymmetric aldol reaction, organosilicon-promoted selective alkyne reduction, Shiina macrolactonization, and a nucleophilic ring-opening of epoxide with alkyne to assemble the main framework of thuggacin A. The enantioselective synthesis of trimethylsilyl ethoxymethyl (SEM) derived thuggacin A analogue 2 was achieved in 18 longest linear steps with 2.0% overall yield, and the bioassay of 2 exhibited moderate antituberculosis activity with minimum inhibitory concentration (MIC) of 320 mu g/mL.


  • Open Access

    Design, Synthesis, and Evaluation of Novel Thiazole-Containing Algicides Inspired by Bacillamide A

    by Xiaoxue Li, Huili Li, Lei Shi, Zuguang Yin, Yuguo Du, Hongxia Zhang, Xin Wang, Xinxin Wang, Kexin Xu, Weili Wang, et al.

    The pursuit of highly effective, low-toxicity, and eco-friendly algicides for controlling and eradicating harmful algal blooms (HABs) is of paramount importance. The natural allelochemical bacillamide A has displayed impressive algicidal activity against harmful algae with favorable safety profiles. However, the poor synthetic efficiency and large dose requirements of bacillamide A limit its further application. In this paper, 17 thiazole-containing bacillamide derivatives (BDs) were designed and synthesized in three linear steps as potential algicides. Eight compounds (6a, 6c, 6j, 7b, 7c, 7d, 7e, and 7g) displayed potent inhibitory effects against Prorocentrum minimum, Skeletonema costatum, and Alexandrium pacificum, and they had similar or better activity than the positive control (CuSO4) and bacillamide A. Compound 6a exhibited the most potent algicidal activity against S. costatum (half-maximal effective concentration [EC50] = 0.11 μg/mL), being 23-fold more potent than bacillamide A, 28-fold more potent than CuSO4, and 39-fold more potent than Diuron. Compound 6j exhibited significant algicidal activity against the toxic dinoflagellates P. minimum (EC50 = 1.0 μg/mL) and A. pacificum (EC50 = 0.47 μg/mL), being 3–5-fold more potent than natural bacillamide A, Diuron, and CuSO4. Micrographs and SEM images revealed that 6j induced cell wall rupture and cellular content leakage. Biochemical and physiological studies indicated that 6j might partially disrupt the antioxidant and photosynthetic systems in algal cells, resulting in morphological changes, cell wall rupture, and inclusion leakage. Our work suggests that 6j has a distinct mode of action from CuSO4 and provides a promising candidate for the development of new algicides, worthy of further investigation.


  • Open Access

    Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme

    by Yuxin Feng, Yingjie Wang, Xiaoxue Li, Ziqiang Sun, Sihan Qiang, Hongbo Wang, Yi Liu

    Glioblastoma multiforme, a highly aggressive and lethal brain tumor, is a substantial clinical challenge and a focus of increasing concern globally. Hematological toxicity and drug resistance of first-line drugs underscore the necessity for new anti-glioma drug development. Here, 43 anthracenyl skeleton compounds as p53 activator XI-011 analogs were designed, synthesized, and evaluated for their cytotoxic effects. Five compounds (13d, 13e, 14a, 14b, and 14n) exhibited good anti-glioma activity against U87 cells, with IC50 values lower than 2 μM. Notably, 13e showed the best anti-glioma activity, with an IC50 value up to 0.53 μM, providing a promising lead compound for new anti-glioma drug development. Mechanistic analyses showed that 13e suppressed the MDM4 protein expression, upregulated the p53 protein level, and induced cell cycle arrest at G2/M phase and apoptosis based on Western blot and flow cytometry assays.


  • Convenient total synthesis of Bistratamides H and J

    by Ziqiang Sun, Yuxin Feng, Shuqi Liu, Xiaoxue Li, Sihan Qiang, Guoying Zhang, Huili Liu, Hongbo Wang, Yi Liu


  • Discovery of N-alkyl-N-benzyl thiazoles as novel TRPC antagonists for the treatment of glioblastoma multiforme

    by Shanshan Wang, Xiaoxue Li, Yuemiao Hu, Lin Wang, Guangyao Lv, Yuxin Feng, Ziqiang Sun, Zhengyu Cao, Yi Liu, Hongbo Wang


  • Open Access

    Identification of and Structural Insights into Hit Compounds Targeting N-Myristoyltransferase for Cryptosporidium Drug Development

    by Michael K. Fenwick, Alexandra R. Reers, Yi Liu, Rachael Zigweid, Banumathi Sankaran, Janis Shin, Matthew A. Hulverson, Bradley Hammerson, Elena Fernández Álvaro, Peter J. Myler, et al.

    Each year, approximately 50,000 children under 5 die as a result of diarrhea caused by Cryptosporidium parvum, a protozoan parasite. There are currently no effective drugs or vaccines available to cure or prevent Cryptosporidium infection, and there are limited tools for identifying and validating targets for drug or vaccine development. We previously reported a high throughput screening (HTS) of a large compound library against Plasmodium N-myristoyltransferase (NMT), a validated drug target in multiple protozoan parasite species. To identify molecules that could be effective against Cryptosporidium, we counter-screened hits from the Plasmodium NMT HTS against Cryptosporidium NMT. We identified two potential hit compounds and validated them against CpNMT to determine if NMT might be an attractive drug target also for Cryptosporidium. We tested the compounds against Cryptosporidium using both cell-based and NMT enzymatic assays. We then determined the crystal structure of CpNMT bound to Myristoyl-Coenzyme A (MyrCoA) and structures of ternary complexes with MyrCoA and the hit compounds to identify the ligand binding modes. The binding site architectures display different conformational states in the presence of the two inhibitors and provide a basis for rational design of selective inhibitors.


  • First Total Synthesis of 27-Deoxylyngbyabellin A

    by Yi Liu, Yuguo Du, Yang Zhang

    In this study, we document the first total synthesis of the marine cyanobacteria secondary metabolite 27-deoxylyngbyabellin A in 10 linear steps with 9.7% overall yield. Key steps entailed (1) one-pot cascade reaction of (S)-2-(benzyloxy)-3-methylbutanoic acid and of Boc-l-Ile-OH with a β-azido disulfide building block to access two critical thiazole units, (2) chiral oxazaborolidinone-mediated asymmetric aldol reaction to construct an (S)-β-hydroxy ester, and (3) diphenyl phosphorazidate mediated macrolactamization of the assembled linear precursor to achieve the natural product 27-deoxylyngbyabellin A.